APA
Click to copy
Álvarez-Heredia, P., Reina-Alfonso, I., Domínguez-Del-Castillo, J., Hassouneh, F., Gutiérrez-González, C., Batista-Duharte, A., … Pera, A. (2023). Spanish HCMV Seroprevalence in the 21st Century. Viruses.
Chicago/Turabian
Click to copy
Álvarez-Heredia, Pablo, Irene Reina-Alfonso, J. Domínguez-Del-Castillo, Fakhri Hassouneh, Carmen Gutiérrez-González, Alexander Batista-Duharte, Ana-Belén Pérez, et al. “Spanish HCMV Seroprevalence in the 21st Century.” Viruses (2023).
MLA
Click to copy
Álvarez-Heredia, Pablo, et al. “Spanish HCMV Seroprevalence in the 21st Century.” Viruses, 2023.
BibTeX Click to copy
@article{pablo2023a,
title = {Spanish HCMV Seroprevalence in the 21st Century},
year = {2023},
journal = {Viruses},
author = {Álvarez-Heredia, Pablo and Reina-Alfonso, Irene and Domínguez-Del-Castillo, J. and Hassouneh, Fakhri and Gutiérrez-González, Carmen and Batista-Duharte, Alexander and Pérez, Ana-Belén and Sarramea, Fernando and Jaén-Moreno, M. J. and Camacho-Rodríguez, Cristina and Tarazona, R. and Solana, Rafael and Molina, Juan and Pera, A.}
}
Human cytomegalovirus (HCMV) is linked to age-related diseases like cardiovascular disease, neurodegenerative conditions, and cancer. It can also cause congenital defects and severe illness in immunocompromised individuals. Accurate HCMV seroprevalence assessment is essential for public health planning and identifying at-risk individuals. This is the first HCMV seroprevalence study conducted in the general Spanish adult population in 30 years. We studied HCMV seroprevalence and HCMV IgG antibody titres in healthy adult donors (HDs) and HCMV-related disease patients from 2010 to 2013 and 2020 to 2023, categorized by sex and age. We compared our data with 1993 and 1999 studies in Spain. The current HCMV seroprevalence among HDs in Spain is 73.48%. In women of childbearing age, HCMV seroprevalence has increased 1.4-fold in the last decade. HCMV-seropositive individuals comprise 89.83% of CVD patients, 69% of SMI patients, and 70.37% of COVID-19 patients. No differences in HCMV seroprevalence or HCMV IgG antibody titres were observed between patients and HDs. A significant reduction in Spanish HCMV seroprevalence among HDs was observed in 1993. However, women of childbearing age have shown an upturn in the last decade that may denote a health risk in newborns and a change in HCMV seroprevalence trends.